Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd specializes in medical device and pharmaceutical trading.[1]
- Market Cap ₹ 37.4 Cr.
- Current Price ₹ 70.0
- High / Low ₹ 256 / 66.0
- Stock P/E 12.4
- Book Value ₹ 62.0
- Dividend Yield 0.00 %
- ROCE 13.9 %
- ROE 10.4 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.13 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 11.3% over last 3 years.
- Debtor days have increased from 119 to 149 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 6m | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 8.03 | 18.96 | 27.64 | 37.75 | |
| 7.09 | 16.59 | 23.39 | 32.93 | |
| Operating Profit | 0.94 | 2.37 | 4.25 | 4.82 |
| OPM % | 11.71% | 12.50% | 15.38% | 12.77% |
| 0.01 | 0.03 | 0.08 | 0.09 | |
| Interest | 0.00 | 0.09 | 0.18 | 0.80 |
| Depreciation | 0.00 | 0.01 | 0.02 | 0.05 |
| Profit before tax | 0.95 | 2.30 | 4.13 | 4.06 |
| Tax % | 26.32% | 26.09% | 26.15% | 25.62% |
| 0.70 | 1.70 | 3.04 | 3.01 | |
| EPS in Rs | 2.03 | 3.47 | 6.12 | 5.63 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -70% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 11% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 4.90 | 4.97 | 5.35 | |
| Reserves | 13.44 | 19.60 | 27.83 | |
| 1.60 | 3.26 | 8.99 | ||
| 0.94 | 3.02 | 3.94 | ||
| Total Liabilities | 20.88 | 30.85 | 46.11 | |
| 0.05 | 1.65 | 1.82 | ||
| CWIP | 0.00 | 0.00 | 0.00 | |
| Investments | 0.43 | 0.44 | 4.43 | |
| 20.40 | 28.76 | 39.86 | ||
| Total Assets | 20.88 | 30.85 | 46.11 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -0.79 | 1.80 | -3.58 | ||
| -4.55 | -11.07 | -0.65 | ||
| 13.10 | 2.89 | 5.66 | ||
| Net Cash Flow | 7.77 | -6.39 | 1.43 | |
| Free Cash Flow | -0.82 | 0.18 | -3.80 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -33% | 58% | -49% |
Ratios
Standalone / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 90.48 | 117.79 | 149.29 | |
| Inventory Days | 6.27 | 53.66 | 106.73 | |
| Days Payable | 0.46 | 22.43 | 2.95 | |
| Cash Conversion Cycle | 96.29 | 149.02 | 253.07 | |
| Working Capital Days | 118.78 | 100.63 | 142.13 | |
| ROCE % | 18.04% | 13.89% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Geographic Presence (States/UTs) count |
|
|
| Permanent Employees count |
||
| New Products Launched count |
||
| Satisfied Customers count |
||
| Total Product Portfolio count |
||
| US FDA Approvals Obtained count |
||
Extracted by Screener AI
Documents
Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 5Th October, 2026
- Board approved internal auditor A G H A & Associates and secretarial auditor Mayuri Sinha & Co. for FY2026-27.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Shareholder Meeting / Postal Ballot-Outcome of AGM
-
Closure of Trading Window
- Trading window closed from 1 October 2026 until 48 hours after half-year results.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
Business Overview:[1][2]
RSL deals in Advanced medical devices, pharmaceuticals, diagnostics, and offers surgical solutions. It provides hospitals, laboratories, clinics, and institutions
with products like surgical accessories, instruments, equipment, consumables,
reagents, diagnostic kits, and disposable
medical supplies